Previous close | 1.6500 |
Open | 1.7500 |
Bid | 1.6900 x 1400 |
Ask | 1.7200 x 1800 |
Day's range | 1.6500 - 1.7500 |
52-week range | 0.9200 - 3.7900 |
Volume | |
Avg. volume | 4,571,537 |
Market cap | 418.603M |
Beta (5Y monthly) | 1.27 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Despite a net loss, Lexicon Pharmaceuticals Inc (LXRX) shows promising advancements in drug development and strategic financial maneuvers.
Lexicon (LXRX) delivered earnings and revenue surprises of -11.11% and 3.09%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Exploring the Financial and Operational Milestones of Lexicon Pharmaceuticals in the First Quarter of 2024